Literature DB >> 28324319

White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration.

Lucette A Cysique1,2,3, James R Soares4, Guangqiang Geng4, Maia Scarpetta4, Kirsten Moffat5, Michael Green4, Bruce J Brew6,7,8,9, Roland G Henry10, Caroline Rae4,6.   

Abstract

The objective of the current study was to quantify the degree of white matter (WM) abnormalities in chronic and virally suppressed HIV-infected (HIV+) persons while carefully taking into account demographic and disease factors. Diffusion tensor imaging (DTI) was conducted in 40 HIV- and 82 HIV+ men with comparable demographics and life style factors. The HIV+ sample was clinically stable with successful viral control. Diffusion was measured across 32 non-colinear directions with a b-value of 1000 s/mm2; fractional anisotropy (FA) and mean diffusivity (MD) maps were quantified with Itrack IDL. Using the ENIGMA DTI protocol, FA and MD values were extracted for each participant and in 11 skeleton regions of interest (SROI) from standard labels in the JHU ICBM-81 atlas covering major striato-frontal and parietal tracks. We found no major differences in FA and MD values across the 11 SROI between study groups. Within the HIV+ sample, we found that a higher CNS penetrating antiretroviral treatment, higher current CD4+ T cell count, and immune recovery from the nadir CD4+ T cell count were associated with increased FA and decreased MD (p < 0.05-0.006), while HIV duration, symptomatic, and asymptomatic cognitive impairment were associated with decreased FA and increased MD (p < 0.01-0.004). Stability of HIV treatment and antiretroviral CNS penetration efficiency in addition to current and historical immune recovery were related to higher FA and lower MD (p = 0.04-p < 0.01). In conclusion, WM DTI measures are near normal except for patients with neurocognitive impairment and longer HIV disease duration.

Entities:  

Keywords:  Antiretroviral treatment; Diffusion tensor imaging; HIV-associated neurocognitive disorder; HIV/AIDS; Immune functions

Mesh:

Substances:

Year:  2017        PMID: 28324319     DOI: 10.1007/s13365-017-0524-1

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  38 in total

Review 1.  Advances in functional and structural MR image analysis and implementation as FSL.

Authors:  Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

2.  Facial emotional processing in HIV infection: relation to neurocognitive and neuropsychiatric status.

Authors:  Tammy A Lane; Danielle M Moore; Jennifer Batchelor; Bruce J Brew; Lucette A Cysique
Journal:  Neuropsychology       Date:  2012-09-17       Impact factor: 3.295

3.  The physical and biological basis of quantitative parameters derived from diffusion MRI.

Authors:  Gavin P Winston
Journal:  Quant Imaging Med Surg       Date:  2012-12

4.  Methodological considerations on tract-based spatial statistics (TBSS).

Authors:  Michael Bach; Frederik B Laun; Alexander Leemans; Chantal M W Tax; Geert J Biessels; Bram Stieltjes; Klaus H Maier-Hein
Journal:  Neuroimage       Date:  2014-06-16       Impact factor: 6.556

5.  Frontostriatal fiber bundle compromise in HIV infection without dementia.

Authors:  Adolf Pfefferbaum; Margaret J Rosenbloom; Torsten Rohlfing; Carol A Kemper; Stanley Deresinski; Edith V Sullivan
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

6.  Age exacerbates HIV-associated white matter abnormalities.

Authors:  Talia R Seider; Assawin Gongvatana; Adam J Woods; Huaihou Chen; Eric C Porges; Tiffany Cummings; Stephen Correia; Karen Tashima; Ronald A Cohen
Journal:  J Neurovirol       Date:  2015-10-07       Impact factor: 2.643

7.  HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research.

Authors:  Lucette A Cysique; Robert K Heaton; Jody Kamminga; Tammy Lane; Thomas M Gates; Danielle M Moore; Emma Hubner; Andrew Carr; Bruce J Brew
Journal:  J Neurovirol       Date:  2014-04-03       Impact factor: 2.643

8.  White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment.

Authors:  Tanja Su; Matthan W A Caan; Ferdinand W N M Wit; Judith Schouten; Gert J Geurtsen; James H Cole; David J Sharp; Frans M Vos; Maria Prins; Peter Portegies; Peter Reiss; Charles B Majoie
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

9.  Diffusion tensor and volumetric magnetic resonance measures as biomarkers of brain damage in a small animal model of HIV.

Authors:  Margaret R Lentz; Kristin L Peterson; Wael G Ibrahim; Dianne E Lee; Joelle Sarlls; Martin J Lizak; Dragan Maric; William C Reid; Dima A Hammoud
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

10.  Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.

Authors:  Jan Jessen Krut; Tomas Mellberg; Richard W Price; Lars Hagberg; Dietmar Fuchs; Lars Rosengren; Staffan Nilsson; Henrik Zetterberg; Magnus Gisslén
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more
  14 in total

1.  In vivo characterization of macrophage-tropic simian immunodeficiency virus molecular clones in rhesus macaques.

Authors:  Sanjeev Gumber; Praveen Kumar Amancha; Po-Jen Yen; Francois Villinger; Dana Gabuzda; Siddappa N Byrareddy
Journal:  J Neurovirol       Date:  2018-03-28       Impact factor: 2.643

2.  Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities.

Authors:  Laura M Campbell; Christine Fennema-Notestine; Rowan Saloner; Mariam Hussain; Anna Chen; Donald Franklin; Anya Umlauf; Ronald J Ellis; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned Sacktor; Susan Morgello; J Allen McCutchan; Scott Letendre; Igor Grant; Robert K Heaton
Journal:  J Int Neuropsychol Soc       Date:  2019-10-02       Impact factor: 2.892

3.  Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  J Neurovirol       Date:  2019-01-11       Impact factor: 2.643

4.  Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.

Authors:  Jacqueline Rosenthal; William Tyor
Journal:  J Neurovirol       Date:  2019-03-13       Impact factor: 2.643

5.  Associations of alcohol use, HIV infection, and age with brain white matter microstructure.

Authors:  Mollie A Monnig; Joseph M Gullett; Eric C Porges; Adam J Woods; Peter M Monti; Karen Tashima; Neda Jahanshad; Paul Thompson; Talia Nir; Ronald A Cohen
Journal:  J Neurovirol       Date:  2021-11-08       Impact factor: 3.739

6.  Machine learning prediction of neurocognitive impairment among people with HIV using clinical and multimodal magnetic resonance imaging data.

Authors:  Yunan Xu; Yizi Lin; Ryan P Bell; Sheri L Towe; John M Pearson; Tauseef Nadeem; Cliburn Chan; Christina S Meade
Journal:  J Neurovirol       Date:  2021-01-19       Impact factor: 2.643

Review 7.  Mechanisms of neuronal dysfunction in HIV-associated neurocognitive disorders.

Authors:  Elena Irollo; Jared Luchetta; Chunta Ho; Bradley Nash; Olimpia Meucci
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

8.  Semaphorin4A causes loss of mature oligodendrocytes and demyelination in vivo.

Authors:  Brian Chiou; Elizabeth Neely; Asha Kallianpur; James R Connor
Journal:  J Neuroinflammation       Date:  2019-02-08       Impact factor: 8.322

9.  Axonal chronic injury in treatment-naïve HIV+ adults with asymptomatic neurocognitive impairment and its relationship with clinical variables and cognitive status.

Authors:  Rui-Li Li; Jun Sun; Zhen-Chao Tang; Jing-Ji Zhang; Hong-Jun Li
Journal:  BMC Neurol       Date:  2018-05-10       Impact factor: 2.474

10.  Effects of age, HIV, and HIV-associated clinical factors on neuropsychological functioning and brain regional volume in HIV+ patients on effective treatment.

Authors:  Natalia Gawron; M Choiński; B Szymańska-Kotwica; A Pluta; M Sobańska; A R Egbert; A Desowska; T Wolak; A Horban; E Firląg-Burkacka; P Bieńkowski; H Sienkiewicz-Jarosz; A Scińska-Bieńkowska; B Biswal; S M Rao; R Bornstein; E Łojek
Journal:  J Neurovirol       Date:  2018-10-08       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.